Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 6/20 | 0.59 |
| ▸ | CES1 | P23141 | 5/20 | 0.59 |
| ▸ | CES2 | O00748 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 6/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4296205 | 1.00 | FAAH (0.59) | FAAHCES1CES2CA2MEN1 | |
| SCHEMBL4336247 | 1.00 | FAAH (0.59) | FAAHCES1CES2CA2MEN1 | |
| SCHEMBL4668255 | 1.00 | FAAH (0.59) | FAAHCES1CES2CA2MEN1 | |
| SCHEMBL4314502 | 0.98 | FAAH (0.56) | FAAHCES1CES2CA2MEN1 | |
| SCHEMBL6637023 | 0.83 | CA2 (0.55) | FAAHCES1CES2CA2MEN1 | |
| SCHEMBL4731981 | 0.83 | FAAH (0.57) | FAAHCES1CES2CA2MEN1 | |
| SCHEMBL4732708 | 0.83 | FAAH (0.57) | FAAHCES1CES2CA2MEN1 | |
| SCHEMBL8759772 | 0.83 | CA2 (0.55) | FAAHCES1CES2CA2MEN1 | |
| SCHEMBL14166661 | 0.83 | FAAH (0.57) | FAAHCES1CES2CA2MEN1 | |
| SCHEMBL4732397 | 0.83 | FAAH (0.57) | FAAHCES1CES2CA2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1991213-A2 | ANTI-MYCOBACTERIAL FORMULATION COMPRISING OCTANESULPHONYLACETAMIDE (OSA), NONANESULPHONYLACETAMIDE (NSA) AND DECANESULPHONYLACETAMIDE (DSA) | Fasgen, Inc. (US) | 2008-11-19 | — | — | EP | claimed |
| US-20070244199-A1 | ANTI-MYCOBACTERIAL FORMULATION | FASGEN INC. (US) | 2007-10-18 | — | — | US | claimed |
| WO-2007092590-A2 | ANTI-MYCOBACTERIAL FORMULATION COMPRISING OCTANESULPHONYLACETAMIDE (OSA), NONANESULPHONYLACETAMIDE (NSA) AND DECANESULPHONYLACETAMIDE (DSA) | FASGEN, INC. (US) | 2007-08-16 | — | — | WO | claimed |
| EP-1991213-A2 | ANTI-MYCOBACTERIAL FORMULATION COMPRISING OCTANESULPHONYLACETAMIDE (OSA), NONANESULPHONYLACETAMIDE (NSA) AND DECANESULPHONYLACETAMIDE (DSA) | Fasgen, Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| US-7385086-B2 | Antimicrobial compounds | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2008-06-10 | — | — | US | disclosed |
| US-7385086-B2 | Antimicrobial compounds | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2008-06-10 | — | — | US | disclosed |
| WO-2007092590-A3 | ANTI-MYCOBACTERIAL FORMULATION COMPRISING OCTANESULPHONYLACETAMIDE (OSA), NONANESULPHONYLACETAMIDE (NSA) AND DECANESULPHONYLACETAMIDE (DSA) | FASGEN INC (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070244199-A1 | ANTI-MYCOBACTERIAL FORMULATION | FASGEN INC. (US) | 2007-10-18 | — | — | US | disclosed |
| WO-2007092590-A2 | ANTI-MYCOBACTERIAL FORMULATION COMPRISING OCTANESULPHONYLACETAMIDE (OSA), NONANESULPHONYLACETAMIDE (NSA) AND DECANESULPHONYLACETAMIDE (DSA) | FASGEN, INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007092590-A2 | ANTI-MYCOBACTERIAL FORMULATION COMPRISING OCTANESULPHONYLACETAMIDE (OSA), NONANESULPHONYLACETAMIDE (NSA) AND DECANESULPHONYLACETAMIDE (DSA) | FASGEN, INC. (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244199-A1 | ANTI-MYCOBACTERIAL FORMULATION | IMMT, TLR5, IFNG | FAAH 3641/4885CES1 3711/4885CES2 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.